The DOI matches its Crossref record; 70 of the 70 references it cites were found in a registry or an index.
The NCI60 human tumour cell line anticancer drug screen
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Mosmann, T. (1983) · Journal of Immunological Methods · doi:10.1016/0022-1759(83)90303-4 · Cited by 56,104
New Colorimetric Cytotoxicity Assay for Anticancer-Drug Screening
Skehan, P., Storeng, R., Scudiero, D., Monks, A., McMahon, J., Vistica, D., Warren, J. T., Bokesch, H., Kenney, S., & Boyd, M. R. (1990) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/82.13.1107 · Cited by 9,766
Monks, A., Scudiero, D., Skehan, P., Shoemaker, R., Paull, K., Vistica, D., Hose, C., Langley, J., Cronise, P., Vaigro-Wolff, A., et al. (1991) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/83.11.757 · Cited by 3,289
Self-citationAlley, M. C., Scudiero, D. A., Monks, A. P., Hursey, M. L., Czerwiński, M., Fine, D. L., Abbott, B. J., Mayo, J. G., Shoemaker, R. H., & Boyd, M. R. (1988) · PubMed · Cited by 3,082
Self-citationScudiero, D. A., Shoemaker, R. H., Paull, K. D., Monks, A. P., Tierney, S., Nofziger, T. H., Currens, M. J., Seniff, D. A., & Boyd, M. R. (1988) · PubMed · Cited by 2,342
Self-citationSystematic variation in gene expression patterns in human cancer cell lines
Ross, D. T., Scherf, U., Eisen, M. B., Perou, C. M., Rees, C., Spellman, P., Iyer, V., Jeffrey, S. S., Van de Rijn, M., Waltham, M., et al. (2000) · Nature Genetics · doi:10.1038/73432 · Cited by 2,088
Boyd, M. R., & Paull, K. D. (1995) · Drug Development Research · doi:10.1002/ddr.430340203 · Cited by 1,572
Garraway, L. A., Widlund, H. R., Rubin, M. A., Getz, G., Berger, A. J., Ramaswamy, S., Beroukhim, R., Milner, D. A., Granter, S. R., Du, J., et al. (2005) · Nature · doi:10.1038/nature03664 · Cited by 1,548
Proteasome inhibitors: a novel class of potent and effective antitumor agents.
Adams, J., Palombella, V. J., Sausville, E. A., Johnson, J. I., Destree, A. T., Lazarus, D. D., Maas, J., Pien, C. S., Prakash, S., & Elliott, P. J. (1999) · PubMed · Cited by 1,477
A gene expression database for the molecular pharmacology of cancer
Scherf, U., Ross, D. T., Waltham, M., Smith, L. H., Lee, J. K., Tanabe, L., Kohn, K. W., Reinhold, W. C., Myers, T. G., Andrews, D. T., et al. (2000) · Nature Genetics · doi:10.1038/73439 · Cited by 1,450
Cited by
Items 101–117 of 117
Moran, D. M., Trusk, P. B., Pry, K., Paz, K., Sidransky, D., & Bacus, S. S. (2014) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-13-0649 · Cited by 64
Computational models for predicting drug responses in cancer research
Azuaje, F. (2016) · Briefings in Bioinformatics · doi:10.1093/bib/bbw065 · Cited by 59
Fowles, J. S., Dailey, D. D., Gustafson, D. L., Thamm, D. H., & Duval, D. L. (2017) · Veterinary and Comparative Oncology · doi:10.1111/vco.12192 · Cited by 49
Computational identification of multi-omic correlates of anticancer therapeutic response
Stetson, L. C., Pearl, T., Chen, Y., & Barnholtz-Sloan, J. S. (2014) · BMC Genomics · doi:10.1186/1471-2164-15-s7-s2 · Cited by 49
False and mycoplasma-contaminated leukemia-lymphoma cell lines: time for a reappraisal
Drexler, H. G., Dirks, W. G., MacLeod, R. A. F., & Uphoff, C. C. (2017) · International Journal of Cancer · doi:10.1002/ijc.30530 · Cited by 45
Shee, K., Wells, J. D., Jiang, A., & Miller, T. W. (2019) · PLOS ONE · doi:10.1371/journal.pone.0224267 · Cited by 43
Jacobi, N., Seeboeck, R., Hofmann, E., Schweiger, H., Smolinska, V., Mohr, T., Boyer, A., Sommergruber, W., Lechner, P., Pichler-Huebschmann, C., et al. (2017) · Oncotarget · doi:10.18632/oncotarget.22475 · Cited by 43
deepOrganoid: a brightfield cell viability model for screening matrix-embedded organoids
Powell, R. T., Moussalli, M. J., Guo, L., Bae, G., Singh, P., Stephan, C., Shureiqi, I., & Davies, P. J. (2022) · SLAS Discovery · doi:10.1016/j.slasd.2022.03.004 · Cited by 37
The opportunities of mining historical and collective data in drug discovery
Wassermann, A. M., Lounkine, E., Davies, J. W., Glick, M., & Camargo, L. M. (2015) · Drug Discovery Today · doi:10.1016/j.drudis.2014.11.004 · Cited by 34
Computational estimation of quality and clinical relevance of cancer cell lines
Trastulla, L., Noorbakhsh, J., Vazquez, F., McFarland, J., & Iorio, F. (2022) · Molecular Systems Biology · doi:10.15252/msb.202211017 · Cited by 31
“Starting from the pioneer NCI-60 panel, created in the 1980s (Shoemaker, 2006) and aimed at identifying compounds with tumour-type-specific growth-inhibitory effects across 60 CCLs, next-generation high-throughput techniques have given rise to large-scale pharmacogenomic screens (Sharma et al ,…”
MethodModels of renal cell carcinoma used to investigate molecular mechanisms and develop new therapeutics
Shapiro, D. D., Virumbrales-Muñoz, M., Beebe, D. J., & Abel, E. J. (2022) · Frontiers in Oncology · doi:10.3389/fonc.2022.871252 · Cited by 28
Chen, X., Pei, L., & Lu, J. (2013) · Complementary Therapies in Medicine · doi:10.1016/j.ctim.2013.01.001 · Cited by 27
Min, D.-J., Vural, S., & Krushkal, J. (2019) · Cancer Genetics · doi:10.1016/j.cancergen.2019.05.005 · Cited by 23
Cell hierarchy, metabolic flexibility and systems approaches to cancer treatment
M. Herst, P., & V. Berridge, M. (2013) · Current Pharmaceutical Biotechnology · doi:10.2174/1389201011314030005 · Cited by 16
Multidimensional profiling in the investigation of small-molecule-induced cell death
Wolpaw, A. J., & Stockwell, B. R. (2014) · Methods in Enzymology · doi:10.1016/b978-0-12-801430-1.00011-1 · Cited by 10
Xie, Y., Peng, J., & Zhou, Y. (2019) · doi:10.21203/rs.2.18936/v1 · Cited by 5
Predicting substrates for orphan solute carrier proteins using multi-omics datasets
Zhang, Y., Newstead, S., & Sarkies, P. (2025) · BMC Genomics · doi:10.1186/s12864-025-11330-5 · Cited by 6
Metadata
- Authors
- Shoemaker, R. H.
- Venue
- Nature Reviews Cancer
- Published
- 2006-10-01
- Volume
- 6
- Issue
- 10
- Pages
- 813-823
- ISSN
- 1474-175X (ISSN-L)
- 1474-1768
- OpenAlex
- W2087312216
- Cited by
- 2,620
- References
- 70
- FWCI
- 3.35
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.